PVLAPVLANASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

seekingalpha.com

Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market

Palvella Therapeutics is positioned as a cautious Buy, driven by strong Phase 3 data for QTORIN rapamycin in microcystic lymphatic malformations (mLM). QTORIN's clinical profile demonstrates high efficacy and a benign safety profile, addressing a major unmet need in mLM and offering first-mover advantage in a niche orphan market. PVLA's mLM program alone could justify a multibillion-dollar valuation, with cVM label expansion potentially doubling revenue opportunity; current cash runway extends well beyond regulatory milestones.

globenewswire.com

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella's lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved therapies

defenseworld.net

Contrasting Palvella Therapeutics (NASDAQ:PVLA) & Silo Pharma (NASDAQ:SILO)

Silo Pharma (NASDAQ: SILO - Get Free Report) and Palvella Therapeutics (NASDAQ: PVLA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk. Risk and Volatility Silo Pharma has a

globenewswire.com

Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

BEYONDmLM.com campaign designed to educate, engage, and empower patients, caregivers , and healthcare professionals

investorplace.com

The Market Has Changed… Have You?

Stock market volatility is rising as algorithms react instantly to global events, forcing investors to rethink traditional strategies.

globenewswire.com

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it closed its previously announced upsized public offering on February 27, 2026. The offering consisted of 1,840,000 shares of its common stock, which included the exercise in full of the underwriters' option to purchase 240,000 additional shares, at a price to the public of $125.00 per share. The aggregate gross proceeds to Palvella from this offering, before deducting underwriting discounts and commissions and offering expenses, were $230.0 million.

defenseworld.net

Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade

Palvella Therapeutics, Inc. (NASDAQ: PVLA - Get Free Report)'s share price gapped up prior to trading on Thursday after Mizuho raised their price target on the stock from $205.00 to $250.00. The stock had previously closed at $128.60, but opened at $140.28. Mizuho currently has an outperform rating on the stock. Palvella Therapeutics shares last traded

globenewswire.com

Palvella Therapeutics Announces Pricing of Upsized Public Offering

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the pricing of its upsized public offering of 1,600,000 shares of its common stock at a price to the public of $125.00 per share. In addition, Palvella has granted the underwriters a 30-day option to purchase up to an additional 240,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The aggregate gross proceeds to Palvella from this offering are expected to be $200 million, before deducting underwriting discounts and commissions and other offering expenses, assuming no exercise of the underwriters' option to purchase additional shares. All shares of common stock are being offered by Palvella. The offering is expected to close on or about February 27, 2026, subject to the satisfaction of customary closing conditions.

globenewswire.com

Palvella Therapeutics Announces Proposed Public Offering

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock. In addition, Palvella expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock.

globenewswire.com

Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Primary endpoint met with statistically significant improvement (mean change of +2.13; p

globenewswire.com

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET Webcast conference call to take place tomorrow, Tuesday, February 24, 2026, at 8:00am ET

defenseworld.net

Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $158.69

Palvella Therapeutics, Inc. (NASDAQ: PVLA - Get Free Report) has received a consensus rating of "Buy" from the seventeen ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have given a strong buy recommendation to the

globenewswire.com

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

WAYNE, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the publication of a systematic review in Clinical and Experimental Dermatology which synthesizes available published clinical evidence on off-label statin use for cutaneous application in porokeratosis. The systematic review supports the scientific rationale and clinical potential for developing Palvella's QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis (DSAP), currently anticipated to enter Phase 2 development in the second half of 2026.

defenseworld.net

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $158.69 Consensus Price Target from Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ: PVLA - Get Free Report) have been given a consensus rating of "Buy" by the seventeen analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, fourteen have given a buy recommendation and two have given a strong buy recommendation

defenseworld.net

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December

Palvella Therapeutics, Inc. (NASDAQ: PVLA - Get Free Report) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 1,326,830 shares, a growth of 60.9% from the December 15th total of 824,522 shares. Based on an average daily volume of 327,392 shares,

globenewswire.com

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

Phase 3 SELVA study evaluating QTORIN™ rapamycin 3.9% anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations (microcystic LMs) remains on track, with topline results anticipated in March 2026; pending positive results, an NDA submission is planned for the second half of 2026

globenewswire.com

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA ® , povorcitinib, ILUMYA®, ODOMZO ® , REMICADE ® , and STELARA ®

seekingalpha.com

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst

Palvella Therapeutics offers a compelling risk/reward profile, underpinned by strong Phase 2 data and a pivotal Phase 3 catalyst in Q1 2026. Palvella's QTORIN rapamycin platform demonstrates high local efficacy with minimal systemic exposure, validated across multiple rare skin disease indications. With $63.6M in cash and a recent $80M raise, Palvella is well-capitalized to reach key data readouts and NDA preparation, minimizing financing risk.

globenewswire.com

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fill an unmet need

feeds.benzinga.com

Palvella: 73% Improved In Phase 2 Study Of Skin Condition Treatment

Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cutaneous venous malformations.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance